The Casimir LGVA study is quickly filling! We are specifically seeking individuals with LGMD2A who can walk across a room and stand up from sitting on a couch to participate. Email LGMDS@casimirtrials.com or call (800)542-0948 for more information.
Pre-registration is now open for the LGMD EL-PFDD Meeting with FDA and other stakeholders
PRE-REGISTER NOW FOR THE LGMD EXTERNALLY-LED PATIENT-FOCUSED DRUG DEVELOPMENT MEETING TO BE HELD ON FRIDAY, SEPTEMBER 23. This no-cost, public virtual meeting is open to those living with LGMD2A, their families and caregivers, physicians, clinicians, industry/pharma representatives, academic researchers, FDA
Limb-girdle muscular dystrophy coalition to host externally-led patient focused drug development meeting
C3 is excited to announce that we’ve teamed up with the LGMD2D Foundation, the Kurt+Peter Foundation, CureLGMD2I, the McColl-Lockwood Laboratory for Muscular Dystrophy Research, and the Speak Foundation to host an Externally-Led Patient Focused Drug Development (EL-PFDD) meeting with the
It’s Official: The LGMD community celebrates adoption of ICD-10 diagnostic codes for LGMD
After a two year campaign, those with LGMD will now have a diagnostic code that matches their diagnosis! C3 is proud to have played a role in this victory alongside our friends and advocacy partners, including the Muscular Dystrophy Association,
C3 funds development of new LGMD2A/R1 disease model for preclinical testing
Coalition to Cure Calpain 3 (C3) is pleased to announce the funding of a new research award to Dr. Pia Elustondo of AGADA Biosciences. This project will characterize a novel LGMD2A/R1 disease model and utilize this model to test several
C3 awards grant to University of Florida researchers to investigate calcium handling in LGMD2A/R1
Coalition to Cure Calpain 3 (C3) is driving LGMD2A/R1 research by awarding a new grant to Dr. Elisabeth Barton and Dr. Lan Wei-LaPierre of the University of Florida. The project is titled “Strategies to improve calcium handling in LGMD2A/R1.” LGMD2A/R1
LGMD diagnostic codes proposed for final implementation
BIG NEWS! New diagnostic codes for those living with LGMD that match their diagnosis are likely on their way! Coalition to Cure Calpain 3 has been working with Muscular Dystrophy Association and other LGMD foundations, patients, and expert physicians to
Do you have questions about LGMD2A/R1?
Coalition to Cure Calpain 3 has answers! Click here to read our recently updated Frequently Asked Questions (FAQs) for patients and families.
Sarepta Therapeutics Q1 Update on LGMD Programs
Sarepta Therapeutics recently published a Community Letter to share updates on their limb-girdle muscular dystrophy gene therapy programs. Click here to access the letter on Sarepta’s website.
Daniel Ferguson LGMD Foundation Launches
C3 is pleased to share the launch of an Australian-based organization, the Daniel Ferguson LGMD Foundation. This registered charity aims to improve the lives of those living with LGMD2A/R1 by improving awareness, increasing genetic testing, and enabling those living with